Therapeuticsmd Inc (NASDAQ:TXMD) Just Reported Decreased Shorts

March 14, 2018 - By Michael Collier

 Therapeuticsmd Inc (NASDAQ:TXMD) Just Reported Decreased Shorts

Investors sentiment increased to 1.73 in Q3 2017. Its up 0.69, from 1.04 in 2017Q2. It increased, as 9 investors sold TherapeuticsMD, Inc. shares while 28 reduced holdings. 24 funds opened positions while 40 raised stakes. 162.04 million shares or 5.51% more from 153.57 million shares in 2017Q2 were reported.
Blackrock Inc stated it has 11.12M shares. Omers Administration owns 34,900 shares or 0% of their US portfolio. The New York-based Oppenheimer And has invested 0.01% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Goldman Sachs Gru Incorporated invested 0% of its portfolio in TherapeuticsMD, Inc. (NASDAQ:TXMD). Td Asset Management Inc reported 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0% or 3,824 shares. Moreover, Raymond James Financial Advisors has 0% invested in TherapeuticsMD, Inc. (NASDAQ:TXMD) for 142,930 shares. Ardsley Advisory Ptnrs holds 25,000 shares or 0.02% of its portfolio. Newtyn Mgmt Lc accumulated 1.80M shares or 1.54% of the stock. Quantbot Technologies L P holds 35,800 shares. Berson And Corrado Investment Advsrs Limited Liability Co invested in 0.16% or 53,125 shares. Moreover, D E Shaw And Incorporated has 0.01% invested in TherapeuticsMD, Inc. (NASDAQ:TXMD) for 709,290 shares. Great West Life Assurance Can reported 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Massachusetts Svcs Company Ma owns 443,294 shares or 0% of their US portfolio. Invesco Limited owns 37,295 shares for 0% of their portfolio.

The stock of Therapeuticsmd Inc (NASDAQ:TXMD) registered a decrease of 1.8% in short interest. TXMD’s total short interest was 52.41 million shares in March as published by FINRA. Its down 1.8% from 53.37M shares, reported previously. With 1.72M shares average volume, it will take short sellers 31 days to cover their TXMD’s short positions. The short interest to Therapeuticsmd Inc’s float is 30.45%.

The stock decreased 0.19% or $0.01 during the last trading session, reaching $5.27. About 696,827 shares traded. TherapeuticsMD, Inc. (NASDAQ:TXMD) has declined 46.30% since March 14, 2017 and is downtrending. It has underperformed by 63.00% the S&P500.

TherapeuticsMD, Inc. operates as a women??s health care product company. The company has market cap of $1.14 billion. The firm makes and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. It currently has negative earnings. The Company’s pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Another recent and important TherapeuticsMD, Inc. (NASDAQ:TXMD) news was published by which published an article titled: “TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and …” on March 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: